did the sino trial randomize over 3,000 inpatients aged 18 to 45 at 32 hospitals in china?
“It enrolled over 3000 hospitalized patients from 32 hospitals across China. Patients were 18 to 45 years old.”
a host said on Psychopharmacology and Psychiatry Updates, 2026-10-09, at 01:19. hear it in context → the speaker cited: the SINO trial.
the episode: Schizophrenia: Which of Seven Antipsychotics Wins? (at 01:19). we link the show's own page; we do not re-host audio.
first, the part that holds
every number in the sentence holds up. the published trial randomized 3,067 inpatients aged 18 to 45 with acutely ill schizophrenia at 32 hospitals, and companion papers on the same cohort place those hospitals in China.
what we found when we went and looked
we read the trial's own abstract (American Journal of Psychiatry, 2026; epub october 2025). it describes a "multicenter (32 hospitals), industry-independent, parallel, assessor-blinded, flexible-dosage randomized trial (Schizophrenia in Non-Occidental Participants)" of "eligible inpatients 18-45 years of age with schizophrenia experiencing acute exacerbation", and states that "a total of 3,067 patients were randomized, of whom 82% completed follow-up." the abstract does not name the country, but its author affiliations are in Beijing. two earlier genetics papers on the same seven-drug, six-week cohort describe "32 psychiatric hospitals in China" and patients "of Han Chinese ethnicity." the host's "over 3000" rounds 3,067 down slightly.
assertion by assertion
| assertion | verdict | what the record says |
|---|---|---|
| the trial enrolled/randomized over 3,000 patients | confirmed | the abstract says 3,067 patients were randomized and 82% completed follow-up. 'over 3000' is accurate and slightly conservative. a 2024 genetics paper on the same cohort reports 3,030, so counts differ a little between reports [1][3] |
| patients were hospitalized | confirmed | the abstract says 'eligible inpatients ... with schizophrenia experiencing acute exacerbation' [1] |
| patients were 18 to 45 years old | confirmed | the abstract says '18-45 years of age' [1] |
| the trial ran at 32 hospitals | confirmed | the abstract says 'multicenter (32 hospitals)' [1] |
| the hospitals were in China | confirmed | the trial abstract does not name the country; its affiliations are Peking University Sixth Hospital, Beijing. a 2018 genetics paper on the same seven-drug, six-week randomized cohort says '32 psychiatric hospitals in China', and a 2024 paper says the patients were 'of Han Chinese ethnicity' and recruited 2010 to 2012. we matched the two by design, not by a shared registry number [1][2][3] |
both directions
for the speaker: the trial abstract confirms 3,067 randomized, inpatients, ages 18 to 45, and 32 hospitals, word for word. the companion genetics papers describe the same cohort (seven antipsychotics, six weeks, Peking University Sixth Hospital as lead site) at 32 psychiatric hospitals in China. the trial's own name, Schizophrenia in Non-Occidental Participants, fits a trial run outside the West.
against: nothing contradicts the sentence. two small points: 'over 3000' undersells 3,067 a little, and the abstract we read never says 'China'. that clause rests on companion papers about what appears to be the same cohort, which report a slightly different patient count (3,030). also, 3,067 is the number randomized, not the number who finished: 82% completed the six weeks. the recruitment years in the companion paper (2010 to 2012) mean the data are more than a decade old, which the quote does not mention.
what this cannot say
we could not open the trial's full text (the journal site blocked our request), so we checked the abstract and indexing record only. we could not read a registry entry that ties the trial to the companion papers' cohort, so that link is by matching design. 'hospitalized' covers inpatient status at enrollment only; how long patients stayed in hospital is not in the abstract. the age limits define who could join; the abstract does not give the actual age spread. our check covers only the enrollment facts in this quote, not the trial's efficacy or side-effect findings.
sources, each one fetched and read
- Efficacy and Tolerability of Seven Antipsychotic Drugs in Acutely Ill Patients With Schizophrenia: A Randomized, Multicenter, Assessor-Blinded Trial. American Journal of Psychiatry, 2026;183(2):112-123. doi:10.1176/appi.ajp.20250111. PMID 41152254 (PubMed record) What we read there: "The authors performed a multicenter (32 hospitals), industry-independent, parallel, assessor-blinded, flexible-dosage randomized trial (Schizophrenia in Non-Occidental Participants). Eligible inpatients 18-45 years of age with schizophrenia experiencing acute exacerbation were recruited..." and "A total of 3,067 patients were randomized, of whom 82% completed follow-up." Fetched 2026-10-16 (HTTP 203). https://pubmed.ncbi.nlm.nih.gov/41152254/
- Five novel loci associated with antipsychotic treatment response in patients with schizophrenia: a genome-wide association study. The Lancet Psychiatry, 2018. PMID 29503163 (PubMed record) What we read there: "The discovery cohort comprised patients with schizophrenia from 32 psychiatric hospitals in China that are part of the Chinese Antipsychotics Pharmacogenomics Consortium," randomly assigned to olanzapine, risperidone, quetiapine, aripiprazole, ziprasidone, and haloperidol or perphenazine for 6 weeks. Fetched 2026-10-16 (HTTP 203). https://pubmed.ncbi.nlm.nih.gov/29503163/
- Contribution of copy number variants on antipsychotic treatment response in Han Chinese patients with schizophrenia. eBioMedicine, 2024. PMC11225184 What we read there: "A total of 3030 patients of Han Chinese ethnicity" were randomly assigned one of seven antipsychotics for six weeks, recruited "from 2010 to 2012"; registered as ChiCTR-TRC-10000934. Fetched 2026-10-16 (HTTP 200). https://pmc.ncbi.nlm.nih.gov/articles/PMC11225184
speakers are described by role, not named. one sentence is quoted under fair use, with attribution and a link to the original at the timestamp; we do not re-host audio or video. nothing on this page is a reason to start, stop or change a medication. if you have the file behind anything marked unverifiable, the research board is where people can answer. adam